The question is WHY?? Pre-Vioxx it wouldn't have?? BIIB caved in to protect its franchise a little longer??? I'm just not sure that BIIB and ELN made the right choice. The damage that was done from the pull, if it turns out to be an acceptable risk no different than ENebrel and Remicade and others, is huge.
That's the issue here. Neurologists would be reluctant to use a drug that could further demyelinate their patients' sheaths. Enbrel is used for rheumatooid arthritis and some other off label uses, including psoriatic arthritis. Remicade is also used for Crohn's disease. Neither of these two drugs are used specifically for MS. Considering the latest finding with Tysabri, which is in a similar pharmacologic class, we might see a warning label with these two other drugs, not to use it with MS patients. Another possible outcome for Tysabri is that it may go back on the market within a year or so for Crohn's, but not for MS. The verdict is still out and we'll have to wait for data. I expect to see more data by the time of the April Neurology Meeting.